Bionano Genomics, Inc. — fact timeline

Alka Chaubey resigned as Chief Medical Officer at Bionano Genomics, Inc..

“On June 2, 2026, Alka Chaubey, Ph.D. resigned as Chief Medical Officer of Bionano Genomics, Inc. (the “Company”) effective July 5, 2026.”

Bionano Genomics, Inc. shareholders approved Ratification of the Selection of Independent Registered Public Accounting Firm at the 2026-05-14 meeting.

“Proposal 3. Ratification of the Selection of Independent Registered Public Accounting Firm. The Company’s stockholders ratified the selection of BDO USA, P.C. by the Audit Committee of the Board of Directors as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026. The final voting results were as follows: Votes For Votes Against Abstentions Broker Non-Votes 3,770,715 206,541 248,739 —”

Bionano Genomics, Inc. shareholders approved Approval, on an Advisory Basis, of the Compensation of the Company’s Named Executive Officers at the 2026-05-14 meeting.

“Proposal 2. Approval, on an Advisory Basis, of the Compensation of the Company’s Named Executive Officers. The Company’s stockholders approved, on an advisory basis, the compensation of the Company’s named executive officers as disclosed in the Company’s definitive proxy statement relating to the Annual Meeting. The final voting results were as follows: Votes For Votes Against Abstentions Broker Non-Votes 697,999 216,553 76,839 3,234,604”

Bionano Genomics, Inc. shareholders approved Election of Directors at the 2026-05-14 meeting.

“Proposal 1. Election of Directors. The Company’s stockholders elected the two persons listed below as Class II Directors, each to serve until the Company’s 2029 Annual Meeting of Stockholders or until their successors are duly elected and qualified or until their earlier death, resignation or removal. The final voting results were as follows: Name Votes For Votes Withheld Broker Non-Votes Albert Luderer, Ph.D. 847,601 143,790 3,234,604 Kristiina Vuori, M.D., Ph.D. 867,474 123,917 3,234,604”

Bionano Genomics, Inc. reported first quarter ended March 31, 2026 results: revenue $6.7 million.

“towards growing our business.” Q1 2026 Financial Results For the three-month period ended March 31, 2026, as compared to the same period of 2025: • Reported total revenue of $6.7 million, representing an increase of 4% from $6.5 million compared to the first quarter of 2025. • Consumables revenue was $3.9 million, representing an increase of 20% compared to the”

Albert A. Luderer was appointed as Interim Chief Executive Officer at Bionano Genomics, Inc..

“As of the Effective Date, the Board appointed Albert A. Luderer, Ph.D., who currently serves as the Company’s Chairman of the Board, as the Company’s Interim Chief Executive Officer.”

Erik Holmlin was terminated as President and Chief Executive Officer at Bionano Genomics, Inc..

“On May 5, 2026 (the “Effective Date”), Bionano Genomics, Inc. (the “Company”) R. Erik Holmlin, Ph.D. was terminated as the Company’s President and Chief Executive Officer, effective immediately.”

Bionano Genomics, Inc.: Filed Certificate of Amendment to effect a 1-for-60 reverse stock split (effective 2025-01-24).

“On January 24, 2025, Bionano Genomics, Inc. (the “ Company ”) filed a Certificate of Amendment to its Amended and Restated Certificate of Incorporation, as amended (the “ Restated Certificate ”), with the office of the Secretary of State of the State of Delaware to effect a reverse stock split at a ratio of 1:60 (the “ Charter Amendment ”).”

Bionano Genomics, Inc. announced a restructuring with charges of $0.5 million to $1.0 million (approximately 84 employees, which represents approximately 45% of its full-time employees as of September 3, 2024).

“an additional $25.0 million to $30.0 million beginning in the fourth quarter of 2024. The Company estimates that it will incur total restructuring charges of approximately $0.5 million to $1.0 million, including severance payments in connection with the Plan. Of the total charges, substantially all charges are expected to be future cash expenditures. The”

Mark Adamchak was appointed as Principal Accounting Officer at Bionano Genomics, Inc..

“Mark Adamchak, Vice President of Accounting & Finance was appointed to serve as the principal accounting officer of the Company, effective September 18, 2024.”

R. Erik Holmlin was appointed as Principal Financial Officer at Bionano Genomics, Inc..

“On September 4, 2024, R. Erik Holmlin, Ph.D., President and Chief Executive Officer of the Company, was appointed by the Board of Directors (the “Board”) of the Company to serve as the principal financial officer of the Company, effective September 18, 2024”

Gülsen Kama departed as Chief Financial Officer at Bionano Genomics, Inc..

“the role of our Chief Financial Officer, Gülsen Kama, was impacted and Ms. Kama will no longer be employed with the Company effective September 18, 2024.”

Bionano Genomics, Inc. reported first quarter ended March 31, 2024 results: revenue $8.8 million. Guidance reaffirmed.

“filing to this Current Report on Form 8-K. --- EX-99.1 (EX-99.1) --- Bionano Reports First Quarter 2024 Results and Highlights Recent Business Progress • Q1 2024 revenue was $8.8 million, which represents an 18% increase over Q1 2023 • Total installed base of 347 optical genome mapping (OGM) systems as of Q1 2024, which represents a 34% increase over Q1 2023 •”

Bionano Genomics, Inc. announced a restructuring with charges of approximately $4.6 million.

“the Reduction is expected to result in total restructuring charges of approximately $4.6 million, including $3.9 million, comprised primarily of severance payments and wages for the 60-day notice period in accordance with the California Worker Adjustment and Retraining Notification (WARN) Act and $0.2 million in connection with lease terminations.”

Bionano Genomics, Inc. entered into Purchase Agreement with certain institutional investors valued at approximately $10.0 million (effective 2024-04-04).

“On April 4, 2024, Bionano Genomics, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with certain institutional investors (the “Purchasers”), pursuant to which the Company agreed to issue and sell, in a registered direct offering priced at-the-market consistent with the rules of the Nasdaq Stock Market (the “Registered Direct Offering”): (i) an aggregate of 6,536,682 shares (the “Shares”) of the Company’s common stock, $0.001 par value per share (the “Common Stock”), (ii) pre-funded warrants to purchase up to an aggregate of 2,196,944 shares of Common Stock (the “Pre-Funded Warrants”), and (iii) warrants to purchase up to 8,733,626 shares of Common Stock (the “Warrants”).”

Bionano Genomics, Inc. reported the fourth quarter and full year ended December 31, 2023 results: revenue $10.7 million.

“Bionano Reports Fourth Quarter and Full-Year 2023 Results and Provides Revenue Outlook for 2024 • Q4 2023 revenue was $10.7 million , which represents a 30% increase over Q4 2022 • FY 2023 revenue was $36.1 million , which represents a 30% increase over FY 2022”

Bionano Genomics, Inc. announced a restructuring affecting global operations (approximately 110 to 125 employees).

“On March 1, 2024, the Company committed to a corporate reorganization plan (the “Plan”), including a reduction in force (the “Reduction”) intended to decrease expenses and maintain a streamlined organization to support key programs that are expected to drive long-term growth.”

Bionano Genomics, Inc. entered into Amendment with High Trail Special Situations LLC (effective 2024-02-27).

“Concurrent with the entry into the Letter Agreement, the Company and the Purchaser entered into an Amendment to Initial Registered Note (the “Amendment”), among other things, to (i) reduce the minimum liquidity covenant under the Initial Registered Note”

Bionano Genomics, Inc. entered into Letter Agreement with High Trail Special Situations LLC valued at total redemption payment of $19,550,000 (effective 2024-02-27).

“On February 27, 2024, the Company entered into a letter agreement (the “Letter Agreement”) with the Purchaser to (i) redeem (a) the entire outstanding principal amount under the Initial Private Placement Note of $17,000,000 from the Purchaser at a redemption price of 115% for a total redemption payment of $19,550,000”

Bionano Genomics, Inc. reported the fiscal year ended December 31, 2023 results: revenue in the range of $35.8 million and $36.1 million.

“Full year 2023 revenue is expected to be in the range of $35.8 million and $36.1 million, an estimated increase of 29% to 30% compared to full year 2022.”

Bionano Genomics, Inc. reported the fourth quarter of 2023 results: revenue in the range of $10.4 million to $10.7 million.

“Revenues for the fourth quarter 2023 are expected to be in the range of $10.4 million to $10.7 million, an estimated increase of 27% to 30% compared to $8.2 million in the fourth quarter of 2022.”

Bionano Genomics, Inc. reported third quarter ended September 30, 2023 results: revenue $9.3 million. Guidance reaffirmed.

“Bionano Reports Third Quarter 2023 Results and Highlights Recent Business Progress • Q3 2023 revenue was $9.3 million, which represents a 29% increase over Q3 2022 • Installed base of Saphyr ® systems totaled 301 as of September 30, 2023, which represents a 39% increase over the number of systems installed as of September 30, 2022 • Sold 6,176 nanochannel array flowcells in Q3 2023, which represents a 55% increase over the number of flowcells sold in Q3 2022”

Bionano Genomics, Inc. reported preliminary financial results for the third quarter of 2023.

“On October 11, 2023, the Company issued a press release announcing certain preliminary performance results for the third quarter of 2023.”

Bionano Genomics, Inc. announced a restructuring with charges of approximately $0.8 million to $1.0 million affecting corporate reorganization plan (approximately 66 employees, which represents 17% of its full-time employees).

“in stock-based compensation, and an expected reduction in cost of goods sold of approximately $1.4 million. The Company expects to incur non-recurring charges of approximately $0.8 million to $1.0 million related to the Reduction, consisting primarily of cash severance payments, employee benefits and related costs. Of the total charges, substantially all charges”

Bionano Genomics, Inc. incurred senior notes of up to an additional $25.0 million aggregate principal amount of Private Placement Notes with High Trail Special Situations LLC maturing 2025.

“and together with the Registered Notes, the “Notes”). Pursuant to the Purchase Agreement, the Company also granted the Purchaser an option to purchase up to an additional $25.0 million aggregate principal amount of Private Placement Notes initially convertible into 8,729,813 shares of the Company’s common stock (the “Subsequently Purchased Notes”) and warrants”

Bionano Genomics, Inc. incurred senior notes of $35.0 million aggregate principal amount of senior secured convertible notes due 2025 with High Trail Special Situations LLC maturing 2025.

“securities purchase agreement (the “Purchase Agreement”) with High Trail Special Situations LLC (the “Purchaser”) pursuant to which the Company agreed to issue and sell , (i) in a”

Bionano Genomics, Inc. incurred senior notes of $45.0 million aggregate principal amount of senior secured convertible notes due 2025 with High Trail Special Situations LLC maturing 2025.

“securities purchase agreement (the “Purchase Agreement”) with High Trail Special Situations LLC (the “Purchaser”) pursuant to which the Company agreed to issue and sell , (i) in a”

Bionano Genomics, Inc. entered into Securities Purchase Agreement with High Trail Special Situations LLC valued at $45.0 million aggregate principal amount of senior secured convertible notes due 2025; $35.0 million (effective 2023-10-11).

“On October 11, 2023, Bionano Genomics, Inc. (the “Company,” “we,” “us,” and “our”) entered into a securities purchase agreement (the “Purchase Agreement”) with High Trail Special Situations LLC (the “Purchaser”)”

Christopher Stewart resigned as Chief Financial Officer at Bionano Genomics, Inc..

“On August 11, 2023, Christopher Stewart resigned as Chief Financial Officer of the Company effective as of September 11, 2023”

Gülsen Kama was appointed as Chief Financial Officer at Bionano Genomics, Inc..

“On August 14, 2023, the Company announced the appointment of Gülsen Kama as Bionano Genomics, Inc.’s (the “Company”) Chief Financial Officer, effective as of September 11, 2023”

Bionano Genomics, Inc. reported second quarter ended June 30, 2023 results: revenue $8.7 million.

“filing to this Current Report on Form 8-K. --- EX-99.1 (EX-99.1) --- Bionano Reports Second Quarter 2023 Results and Highlights Recent Business Progress • Q2 2023 revenue was $8.7 million, which represents a 30% increase over Q2 2022 • Installed base of Saphyr ® systems totaled 281 as of June 30, 2023, which represents a 43% increase over Q2 2022 • Sold 7,062”

Bionano Genomics, Inc.: Filed certificate of elimination to remove designation of Series A Preferred Stock and restore it to undesignated authorized preferred shares (effective 2023-08-04).

“On August 4, 2023, prior to the Company’s filing of the Charter Amendment with the office of the Secretary of State of the State of Delaware, the Company filed a Certificate of Elimination (the “ Certificate of Elimination ”) with the office of the Secretary of State of the State of Delaware with respect to the Company’s Series A Preferred Stock, par value $0.0001 per share (the “ Series A Preferred Stock ”), following the automatic redemption of all outstanding shares of Series A Preferred Stock after the conclusion of the 2023 Annual Meeting.”

Bionano Genomics, Inc.: Amended certificate of incorporation to effect a 1-for-10 reverse stock split (effective 2023-08-04).

“On August 4, 2023, Bionano Genomics, Inc. (the “ Company ”) filed a Certificate of Amendment to its Amended and Restated Certificate of Incorporation, as amended (the “ Restated Certificate ”), with the office of the Secretary of State of the State of Delaware to effect a reverse stock split at a ratio of 1:10 (the “ Charter Amendment ”).”

Bionano Genomics, Inc. shareholders approved Authorization to adjourn the Annual Meeting to solicit additional proxies if necessary at the 2023-06-14 meeting.

“The Company’s stockholders approved the authorization to adjourn the Annual Meeting, if necessary, to solicit additional proxies if there were not sufficient votes in favor of Proposal 4.”

Bionano Genomics, Inc. shareholders approved Approval of a series of alternate amendments to the Company’s Amended and Restated Certificate of Incorporation to effect a reverse stock split at a ratio between 1-for-5 and 1-for-10 at the 2023-06-14 meeting.

“The Company’s stockholders approved a series of alternate amendments to the Company’s Amended and Restated Certificate of Incorporation, as amended, to effect, at the option of the Company’s Board of Directors, a reverse stock split of the Company’s common stock at a ratio between 1-for-5 and 1-for-10, inclusive, as determined by the Company’s Board of Directors in its sole discretion.”

Bionano Genomics, Inc. shareholders approved Ratification of the selection of BDO USA, LLP as independent registered public accounting firm at the 2023-06-14 meeting.

“The Company’s stockholders ratified the selection of BDO USA, LLP by the Audit Committee of the Board as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023.”

Bionano Genomics, Inc. shareholders approved Advisory approval of the compensation of the Company’s named executive officers at the 2023-06-14 meeting.

“The Company’s stockholders approved, on an advisory basis, the compensation of the Company’s named executive officers as disclosed in the Company’s definitive proxy statement relating to the Annual Meeting.”

Bionano Genomics, Inc. shareholders approved Election of Class II Directors at the 2023-06-14 meeting.

“The Company’s stockholders elected the three persons listed below as Class II Directors, each to serve until the Company’s 2026 Annual Meeting of Stockholders or until their successors are duly elected and qualified or until their earlier death, resignation or removal.”

Bionano Genomics, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

“May 30, 2023, Bionano Genomics, Inc. (the “Company”) received a letter (the “Notice”) from The Nasdaq Stock Market LLC (“Nasdaq”) advising the Company that for 30 consecutive trading days preceding the date of the Notice, the bid price of the Company’s common stock had closed below the $1.00 per share minimum required for continued listing on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Requirement”). The Notice has no effect on the listing of the Company’s common stock at this time, and the Company’s common stock continues to trade on The Nasd”

Bionano Genomics, Inc. reported first quarter ended March 31, 2023 results: revenue $7.4 million.

“Total revenue for the first quarter of 2023 was $7.4 million”

Bionano Genomics, Inc. reported first quarter ended March 31, 2023 results: revenue between $7.3 and $7.5 million. Guidance reaffirmed.

“Preliminary Q1 total revenue expected to be between $7.3 and $7.5 million”

Bionano Genomics, Inc.: Amended Section 8 of Article III of Bylaws to reduce stockholder meeting quorum from majority to one-third of stock outstanding and entitled to vote (effective 2023-04-13).

“Effective April 13, 2023, the Board amended Section 8 of Article III of the Company’s Amended and Restated Bylaws to reduce the quorum requirement for all meetings of stockholders of the Company from a majority of the stock outstanding and entitled to vote to one-third of the stock outstanding and entitled to vote.”

Bionano Genomics, Inc.: Filed Certificate of Designation for Series A Preferred Stock establishing preferences, rights, and limitations (effective 2023-04-13).

“On April 13, 2023, in connection with the Purchase Agreement, the Company filed a Certificate of Designation of Preferences, Rights and Limitations of Series A Preferred Stock (the “Series A Certificate of Designation”) with the Secretary of State of the State of Delaware.”

Bionano Genomics, Inc. entered into Purchase Agreement with David Barker valued at $100.00 (effective 2023-04-13).

“On April 13, 2023, Bionano Genomics, Inc. (the “Company”) entered into a Purchase Agreement (the “Purchase Agreement”) with David Barker (“Purchaser”), the Chair of the Company’s Board of Directors (the “Board”), pursuant to which the Company agreed to issue and sell one share of the Company’s newly designated Series A Preferred Stock, par value $0.0001 per share (the “Series A Preferred”), to the Purchaser for a purchase price of $100.00.”

Bionano Genomics, Inc. reported fourth quarter and full year ended December 31, 2022 results: revenue $27.8 million.

“Full year 2022 revenue was $27.8 million , an increase of 55% compared to 2021.”

Bionano Genomics, Inc. reported fourth quarter and fiscal year ended December 31, 2022 results: revenue $8.2 million.

“Report on Form 8-K. --- EX-99.1 (EX-99.1) --- Bionano Genomics Reports Fourth Quarter and Full Year 2022 Results and Provides Revenue Outlook for 2023 • Q4 revenue was $8.2 million , which represents a 30% increase over Q4 2021 • 2022 revenue was $27.8 million , which represents a 55% increase over year end 2021 • Reached installed base of 240 Saphyr®”

Bionano Genomics, Inc. reported full year 2022 results: revenue $27.7 million and $28.0 million.

“As previously announced on January 5, 2022, Bionano Genomics, Inc. (the “Company”), expects to report full year 2022 total revenue in the range of $27.7 million and $28.0 million.”

Bionano Genomics, Inc. reported the year ended December 31, 2022 results: revenue $27.7 million and $28.0 million.

“Full year 2022 revenue is expected to be in the range of $27.7 million and $28.0 million, an estimated increase of between 54% and 56% compared to 2021.”

Bionano Genomics, Inc. reported the fourth quarter of 2022 results: revenue $8.1 million to $8.4 million.

“Revenues for the fourth quarter 2022 are expected to be in the range of $8.1 million to $8.4 million , an estimated increase of 12% to 16% compared to $7.2 million in the third quarter of 2022 and an estimated increase of 27% to 33% compared to the fourth quarter of 2021.”

Bionano Genomics, Inc. completed an acquisition involving Purigen Biosystems, Inc. for approximately $32.0 million in cash (closed 2022-11-30).

“the surviving corporation of the Merger and a wholly owned subsidiary of the Company. Pursuant to the Merger, the Company paid at closing upfront consideration of approximately $32.0 million in cash. The upfront consideration was subject to adjustment for, among other things, cash, unpaid indebtedness, unpaid transaction expenses and net working capital relative to”